TY - JOUR AU - Riadi, AU - Masadah, Rina AU - Nelwan, Berti J. PY - 2021/05/01 Y2 - 2024/03/29 TI - Expression of PD-L1 and Relationship with Tumor-Infiltrating Lymphocytes and Metastasis in Serous Ovarian Carcinoma. JF - International Journal of Sciences: Basic and Applied Research (IJSBAR) JA - IJSBAR VL - 57 IS - 2 SE - Articles DO - UR - https://www.gssrr.org/index.php/JournalOfBasicAndApplied/article/view/12539 SP - 162-170 AB - <p>Ovarian serous carcinoma is the most common ovarian malignancy in women, and most of them are diagnosed at an advanced stage and have metastasis. With current therapy, the 5-year mean survival rate is still not satisfying and opening a new approach. Immunotherapy using anti-PD-L1 is widely used in various types of malignancies. The use of PD-L1 in serous ovarian carcinoma is still quite limited. This study aimed to explore the potential of immunotherapy by assessing the expression of PD-L1 in serous ovarian carcinoma. Immunohistochemical performed to analyze PD-L1 dan compared with metastases incidence and tumor immune response. PD-L1 expression appeared to be stronger in high-grade serous carcinoma than low-grade serous carcinoma, but there was no statistical difference (p 0.539). There was a correlation between PD-L1 and metastasis incident (p 0.015) in high-grade serous ovarian carcinoma. There was a significant correlation between PD-L1 and tumor-infiltrating lymphocytes. PD-L1 in serous carcinoma has a strong relationship with TILs, opens up the possibilities of using anti-PD-L1 on serous carcinoma. PD-L1 expression in high-grade serous carcinoma has a relationship with the incidence of metastases.</p> ER -